Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04780984 · ClinicalTrials.gov registry record · Phase 2
Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease
A Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Nephron Pharmaceuticals Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT04780984: Completed Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Nephron Pharmaceuticals Corporation.
NCT04780984 is a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by Nephron Pharmaceuticals Corporation. The registered enrollment target is 116 participants, below the 648-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04780984, a Phase 2 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by Nephron Pharmaceuticals Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
A Phase 2, Randomized, Partially-blinded, Parallel Group, Dose-ranging Study to Assess the Pharmacodynamics, Relative Bioavailability, and Safety of Three Doses of Tiotropium Bromide Inhalation Solution in Subjects with Chronic Obstructive Pulmonary Disease
Primary Outcome
The primary outcome measure will be the change in trough FEV1 from baseline at Visit 4 in the 8 μg, 16 μg, and 24 μg doses of tiotropium bromide inhalation solution treatment groups compared with that of placebo, will be evaluated by using a mixed model for repeated measure (MMRM) in the mITT population.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tiotropium bromide inhalation solution
Study Locations (1)
South Carolina
- Clinical Research of Rock Hill - Rock Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2020-11-01 |
| Est. Completion | 2021-04-26 |
| Phase | Phase 2 |
What the finished NCT04780984 record still lists
NCT04780984 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 648-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04780984 reports a single indexed study location in South Carolina.
Frequently Asked Questions
What is clinical trial NCT04780984 about?
NCT04780984 is a clinical study titled "Tiotropium Bromide Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease". A Phase 2, Randomized, Partially-blinded, Parallel Group, Dose-ranging Study to Assess the Pharmacodynamics, Relative Bioavailability, and Safety of Three Doses of Tiotropium Bromide Inhalation Solution in Subjects with Chronic Obstructive Pulmonary Disease
What is the current status of trial NCT04780984?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2020-11-01. Estimated completion is 2021-04-26.
What conditions does trial NCT04780984 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT04780984?
The interventions under investigation include: Placebo (DRUG), Tiotropium bromide inhalation solution (DRUG).
Who is sponsoring clinical trial NCT04780984?
This trial is sponsored by Nephron Pharmaceuticals Corporation, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04780984 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04780984's enrollment target sits among peer trials
116 27th of 36 higher than 10 of 36 other Chronic Obstructive Pulmonary Disease (COPD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease (COPD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
RECRUITING · Phase 2
-
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 2
-
Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)
COMPLETED · Phase 2
-
A Phase II, Randomized, Double-blind, Placebo-controlled Study to Assess MEDI3506 in Participants With COPD and Chronic Bronchitis
COMPLETED · Phase 2
-
Sodium Pyruvate Therapy in COPD Patients
COMPLETED · Phase 2
-
Safety and Tolerability of 28 Days Treatment With Glycopyrronium Bromide (NVA237) (100 or 200 µg Once a Day) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI